Evonik Makes First Lipids at Lafayette Center
Evonik's new Lipid Innovation Center in Lafayette, Indiana has produced its first batch of GMP-quality pharmaceutical lipids.
Updated on Nov. 17, 2026 in Business

Evonik has manufactured the first batch of GMP-quality pharmaceutical lipids at its Lipid Innovation Center at the Tippecanoe site in Lafayette, Indiana. The first product from the center is Phytochol, a non-animal-derived cholesterol and essential excipient for lipid nanoparticles.
Why it matters
The center is designed as a flexible facility able to support multiple lipid chemistries, manufacturing processes and products, and it is supported by the U.S. government. Its output is aimed at the lipid nanoparticle supply chain used in pharmaceutical development.
Evonik projects the lipid nanoparticle market will reach 2.7 billion dollars by 2034, while the Lipid Innovation Center is scheduled to reach full capacity by mid-2027. The source does not disclose current output volumes or the basis for the market estimate.
The players
Evonik
Evonik is a German specialty chemicals company with production sites in Germany, the United States and Canada.
The details
Evonik's Lipid Innovation Center is a flexible production site that supports multiple lipid chemistries, manufacturing processes and products. The company operates an integrated global network combining lipid chemistry, LNP formulation, process engineering, sterile manufacturing and regulatory affairs, with late-stage clinical and commercial processes transferred to Birmingham, Alabama.
Timeline
August: Evonik Vancouver Laboratories announced a new GMP facility investment.
Mid-2027: Full capacity of the Lipid Innovation Center is scheduled to come on stream.
2034: The lipid nanoparticle market is projected to reach 2.7 billion dollars.
Manufacturing Context
The Lafayette center adds domestic U.S. capacity for GMP-grade lipids used in lipid nanoparticle delivery systems for mRNA pharmaceuticals. It positions Evonik to supply that growing pharmaceutical manufacturing segment from a U.S. site.
For Lafayette residents, the center adds a local pharmaceutical manufacturing operation at the Tippecanoe site. The source does not describe hiring, job numbers or changes to products available to consumers.
The takeaway
Domestic production of pharmaceutical excipients like Phytochol reduces reliance on overseas supply for the lipid nanoparticle components used in modern drug delivery. Watch whether the center reaches its mid-2027 full-capacity target.
Further reading
Explore more manufacturing news for Lafayette.
Source note: This article includes information reported by Process.






